FierceBiotech1d
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data
Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for ...
Chinese espionage tools deployed in RA World ransomware attack
A China-based threat actor, tracked as Emperor Dragonfly and commonly associated with cybercriminal endeavors, has been observed using in a ransomware attack a toolset previously attributed to ...
Medscape6d
Could Gene Therapy for RA Soon Be Ready to ‘Take Off’?
Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...
Trashing talking Amon-Ra St. Brown says Lions should face Eagles in 2025 season opener
Amon-Ra St. Brown wants Lions to face the Eagles in 2025 NFL season opener: “You would see with our healthy defense how that ...
Purdue Exponent2d
Protesters gather at Smalley Center as admin meets with RA union
Protesters gathered Monday night around the headquarters of University Residences, as administrators inside met with student leaders hoping to unionize RAs on campus.
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.
Targeted Oncology7h
Ongoing Studies of Ra-223–Based Combination Regimens
Evan Y. Yu, MD, discusses other ongoing investigations exploring combinations based on radium-223 (Ra-223), highlighting ...